We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Model Analyzes Cells in Tissue Samples without Need for Trained Pathologist

By LabMedica International staff writers
Posted on 07 Apr 2023
Print article
Image: The tissue biopsy is processed through a tissue grind and then analyzed using real-time deformability cytometry (Photo courtesy of MPL)
Image: The tissue biopsy is processed through a tissue grind and then analyzed using real-time deformability cytometry (Photo courtesy of MPL)

Fast and precise information regarding the operated tissue is crucial for guiding a surgeon's next steps during cancer surgery. In cases where solid tumors are present in a cancer patient, the surgeon typically sends a biopsy sample to a pathologist for a rapid assessment. The pathologist must determine, among other things, whether the tissue is healthy, the extent of cancer's spread into the organs, etc. The traditional intraoperative diagnostic process is laborious, time-consuming, and resource-intensive. Now, scientists have developed a new technique that can perform a reliable analysis of solid tumors in as little as 30 minutes, without the need for a trained pathologist.

A research team from the Max Planck Institute for the Science of Light (MPL, Erlangen, Germany) has created a novel technique that enables clinicians to analyze cells in tissue samples from cancer patients quickly and precisely, without requiring the expertise of a trained pathologist. The team used artificial intelligence (AI) to evaluate the data generated by their method. For their study, the researchers utilized a tissue grinder to quickly tear apart biopsy samples down to the single-cell level. Subsequently, these single cells were analyzed using real-time deformability cytometry (RT-DC), an approach that is label-free and capable of examining the physical properties of up to 1,000 cells per second. This method is 36,000 times faster than the conventional methods used to evaluate cell deformability.

RT-DC involves pushing single cells at high speed through a microscopic channel, where they undergo deformation due to stress and pressure. Images are captured of each cell, which are then utilized by scientists to ascertain a variety of physical characteristics of the cells, including their size, shape, and deformability. However, solely conducting a physical analysis of cells is insufficient for diagnostic purposes. Physicians must be able to interpret these outcomes independently, without the need for the expertise of a trained pathologist or physicist. Therefore, to accomplish this, the researchers combined the tissue grinder and RT-DC with AI. The AI model evaluates the extensive, complex datasets obtained through RT-DC analysis and rapidly assesses whether a biopsy sample comprises cancerous tissue or not. Furthermore, the use of AI confirmed the significance of cell deformability as a biomarker, as the outcomes were markedly inferior when the AI was not trained with this variable.

Overall, the complete procedure, which includes sample processing and automated data analysis, can be executed in under 30 minutes, making it sufficiently fast to be carried out during surgery. One significant advantage of this method is that it does not require the immediate availability of a pathologist to analyze the sample. This is particularly advantageous since intraoperative consultations may not always be feasible, and in some cases, samples can only be examined after the surgery is completed. Based on the results, patients may need to return to the hospital for further surgery, often days later. Aside from testing for tumor presence, this technique was also utilized to detect tissue inflammation in a model of inflammatory bowel disease (IBD). In the future, this method could assist clinicians in evaluating disease severity or distinguishing between various types of IBD. The team aims to eventually transition their method into a clinical setting to support or perhaps even supplant the traditional pathological analysis.

“This was a proof of concept study - the method could accurately determine the presence of tumor tissue in our samples very quickly,” said Dr. Despina Soteriou, a member of the research team. “The next step will be to continue to work very closely with clinicians to determine how this method can best be translated into the clinic.”

Related Links:
MPL 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.